Heavily Pretreated RRMM: Patient Assessment & Treatment Selection

Video

test 2

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Reducing the manufacturing time of CAR T-cell therapy may have a big impact on the treatment of patients with mantle cell lymphoma.
Related Content
When is Nivolumab/Relatlimab Therapy Viable in BRAF+ Melanoma?

When is Nivolumab/Relatlimab Therapy Viable in BRAF+ Melanoma?

Ariana Pelosci
September 18th 2025
Article
Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 18th 2025
Podcast
Previously, in December 2024, CRB-701 was granted FTD by the FDA for relapsed/refractory metastatic cervical cancer.

FDA Grants Fast Track Designation to CRB-701 in Pretreated Recurrent HNSCC

Tim Cortese
September 18th 2025
Article
A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 18th 2025
Podcast
Molecular Characterization of a Rare Glioblastoma Case With Atypical Histopathologic Features

Molecular Characterization of a Rare Glioblastoma Case With Atypical Histopathologic Features

Nanuli Gvazava, MD;Tolga Tuncer, MD;Wei Zhang, MD, PhD;Anup Kasi, MD, MPH;Uma Bhoot
September 18th 2025
Article
Future biomarker analysis will include correlation of efficacy with SLFN11 expression and with markers of DNA damage repair.

Niraparib Triplet Shows PFS Benefit vs Atezolizumab as ES-SCLC Maintenance

Roman Fabbricatore
September 18th 2025
Article